AI Insight
This phase 3 randomized controlled trial (SWOG/NRG S1914) compared stereotactic body radiation therapy (SBRT) combined with atezolizumab immunotherapy versus SBRT alone in patients with high-risk, early-stage non-small-cell lung cancer who were inoperable. The study found no improvement in overall survival when atezolizumab was added to SBRT, and patients receiving the combination therapy experienced more grade 3 or higher adverse events compared to those receiving radiation alone.
Why it matters
This trial provides important evidence that adding immunotherapy to standard radiation treatment does not benefit patients with inoperable early-stage lung cancer and may cause additional harm. The findings will help inform treatment guidelines and prevent unnecessary use of immunotherapy in this patient population, avoiding both increased toxicity and healthcare costs without survival benefit.
Understand the Science
In the first fully reported phase 3 cooperative group trial to assess immunotherapy in inoperable early-stage NSCLC, we observed no improvement in overall survival with atezolizumab plus SBRT, and more grade 3 or higher adverse events were reported with atezolizumab combined with SBRT.